CN102030745B - Dasatinib溶剂合物及其制备方法 - Google Patents
Dasatinib溶剂合物及其制备方法 Download PDFInfo
- Publication number
- CN102030745B CN102030745B CN 201010561241 CN201010561241A CN102030745B CN 102030745 B CN102030745 B CN 102030745B CN 201010561241 CN201010561241 CN 201010561241 CN 201010561241 A CN201010561241 A CN 201010561241A CN 102030745 B CN102030745 B CN 102030745B
- Authority
- CN
- China
- Prior art keywords
- dasatinib
- isopropyl ether
- solvate
- preparation
- crystal formation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
2θ | I/I0% | 2θ | I/I0% |
5.900 | 94 | 24.000 | 40 |
11.860 | 100 | 24.520 | 42 |
13.500 | 11 | 24.860 | 15 |
14.940 | 80 | 25.680 | 11 |
15.720 | 13 | 26.120 | 21 |
16.540 | 21 | 27.300 | 14 |
17.440 | 11 | 27.540 | 14 |
17.840 | 16 | 28.100 | 18 |
18.200 | 19 | 30.200 | 8 |
18.900 | 15 | 31.920 | 7 |
21.120 | 24 | 33.600 | 7 |
21.420 | 44 | 36.680 | 7 |
22.640 | 27 | 38.460 | 7 |
2θ | I/I0% | 2θ | I/I0% |
5.900 | 94 | 24.000 | 40 |
11.860 | 100 | 24.520 | 42 |
13.500 | 11 | 24.860 | 15 |
14.940 | 80 | 25.680 | 11 |
15.720 | 13 | 26.120 | 21 |
16.540 | 21 | 27.300 | 14 |
17.440 | 11 | 27.540 | 14 |
17.840 | 16 | 28.100 | 18 |
18.200 | 19 | 30.200 | 8 |
18.900 | 15 | 31.920 | 7 |
21.120 | 24 | 33.600 | 7 |
21.420 | 44 | 36.680 | 7 |
22.640 | 27 | 38.460 | 7 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010561241 CN102030745B (zh) | 2010-11-26 | 2010-11-26 | Dasatinib溶剂合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010561241 CN102030745B (zh) | 2010-11-26 | 2010-11-26 | Dasatinib溶剂合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102030745A CN102030745A (zh) | 2011-04-27 |
CN102030745B true CN102030745B (zh) | 2012-05-09 |
Family
ID=43884257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010561241 Active CN102030745B (zh) | 2010-11-26 | 2010-11-26 | Dasatinib溶剂合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102030745B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2650524C2 (ru) | 2012-06-15 | 2018-04-16 | Басф Се | Многокомпонентные кристаллы, содержащие дазатиниб и определенные сокристаллобразователи |
EP3024830A2 (en) | 2013-07-25 | 2016-06-01 | Basf Se | Salts of dasatinib in crystalline form |
EP3024831A2 (en) | 2013-07-25 | 2016-06-01 | Basf Se | Salts of dasatinib in amorphous form |
US20180230140A1 (en) | 2014-06-30 | 2018-08-16 | Basf Se | Multicomponent crystals of dasatinib with menthol or vanillin |
CN105030778A (zh) * | 2015-09-22 | 2015-11-11 | 青岛华之草医药科技有限公司 | 一种治疗血癌的药物达沙替尼组合物颗粒剂 |
SG11202000098RA (en) | 2017-07-07 | 2020-02-27 | Biocon Ltd | Polymorphic forms of dasatinib |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1980909B (zh) * | 2004-02-06 | 2010-08-25 | 布里斯托尔-迈尔斯·斯奎布公司 | 作为激酶抑制剂的2-氨基噻唑-5-芳香族甲酰胺的制备方法 |
ES2565521T5 (es) * | 2007-10-23 | 2019-12-10 | Teva Pharma | Polimorfos de dasatinib y proceso para la preparación de los mismos |
WO2010062715A2 (en) * | 2008-11-03 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib and process for preparation thereof |
WO2010067374A2 (en) * | 2008-12-08 | 2010-06-17 | Hetero Research Foundation | Polymorphs of dasatinib |
CN102040596A (zh) * | 2009-10-10 | 2011-05-04 | 上海希迪制药有限公司 | 达沙替尼多晶型物及其制备方法 |
CN101891738B (zh) * | 2010-02-08 | 2011-09-28 | 南京卡文迪许生物工程技术有限公司 | 达沙替尼多晶型物及其制备方法和药用组合物 |
-
2010
- 2010-11-26 CN CN 201010561241 patent/CN102030745B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102030745A (zh) | 2011-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102030745B (zh) | Dasatinib溶剂合物及其制备方法 | |
CN101781269B (zh) | 4-叔丁基-2-(硝基苄亚氨基)噻唑衍生物及其制备方法与应用 | |
CN103833626B (zh) | 西达本胺的晶型及其制备方法与应用 | |
WO2013033922A1 (zh) | 金属镍-咪唑手性纳米笼配合物及其制备方法 | |
CN108774270B (zh) | 靶向于人肺癌耐药细胞的索拉非尼抗肿瘤铂(ii)配合物及其制备方法与应用 | |
CN104356072A (zh) | 5-氟尿嘧啶药物共晶及其制备方法 | |
CN107936263B (zh) | 一种具有光反应活性的配位聚合物及其制备方法和应用 | |
CN102311382B (zh) | 罗氟司特的晶态及其制备方法 | |
CN102643275A (zh) | 一种达莎替尼n-6晶型新的制备方法 | |
CN106795159A (zh) | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 | |
CN103833755A (zh) | 阿哌沙班晶型b及其制备方法 | |
CN104926872B (zh) | 替诺福韦艾拉酚胺半酒石酸盐 | |
CN104910135A (zh) | 右旋雷贝拉唑钠新晶型的制备方法 | |
CN106986871B (zh) | 一种氘代Palbociclib的晶型及其制备方法和应用 | |
WO2022000265A1 (zh) | 一种阿西替尼与戊二酸共晶及其制备方法 | |
CN104140414B (zh) | 阿昔替尼晶型的制备方法 | |
CN106946764A (zh) | 一种制备哌马色林半酒石酸盐晶型b的方法 | |
CN104817536A (zh) | 适合药用的甲磺酸伊马替尼非针状α晶型及其制备方法 | |
CN108794530A (zh) | 一种替诺福韦丙酚酰胺盐晶型及其制备方法和用途 | |
CN103664771B (zh) | 索拉非尼的晶型a及其制备方法 | |
CN102838594A (zh) | 一种达沙替尼的制备及精制方法 | |
CN104558034A (zh) | 磷酸特地唑胺二钠盐的新晶型及其制备方法 | |
CN106029664A (zh) | 一种酪氨酸激酶抑制剂的苹果酸盐的结晶形式及其制备方法 | |
WO2013120496A1 (en) | Process for the preparation of linezolid in crystalline form and salts thereof | |
CN113999216B (zh) | 一种制备医药中间体3-(1h-吲哚基-3-羰基)-2h-色烯-2-酮衍生物的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANGSU SIMCERE PHARMACEUTICAL CO., LTD. Effective date: 20150624 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150624 Address after: 210042 Xuanwu Avenue, Jiangsu, Nanjing, No. 699 -18 Patentee after: Jiangsu Simcere Pharmaceutical Research Company Limited Patentee after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu Avenue, Jiangsu, Nanjing, No. 699 -18 Patentee before: Jiangsu Simcere Pharmaceutical Research Company Limited |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160728 Address after: 210042 Xuanwu District, Xuanwu District, Jiangsu, Nanjing No. 699 -18 Patentee after: Jiangsu Simcere Pharmaceutical Co., Ltd. Address before: 210042 Xuanwu Avenue, Jiangsu, Nanjing, No. 699 -18 Patentee before: Jiangsu Simcere Pharmaceutical Research Company Limited Patentee before: Jiangsu Simcere Pharmaceutical Co., Ltd. |